(Q35689226)

English

Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations

scientific article published on 21 November 2011

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

based on heuristic

inferred from title

author name string

L J Else

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

M Douglas

2

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

L Dickinson

3

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

D J Back

4

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

S H Khoo

5

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

G P Taylor

6

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

language of work or name

0 references

publication date

21 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

56

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

816-824

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Lopinavir tablet pharmacokinetics with an increased dose during pregnancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

12 July 2018

Lopinavir protein binding in HIV-1-infected pregnant women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

12 July 2018

Clinical pharmacology of HIV protease inhibitors in pregnancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

12 July 2018

Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

12 July 2018

Lopinavir exposure with an increased dose during pregnancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

12 July 2018

Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

12 July 2018

Antiretroviral pharmacokinetic profile: a review of sex differences

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

12 July 2018

Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

12 July 2018

Reduction in preterm delivery and neonatal mortality after the introduction of antenatal cotrimoxazole prophylaxis among HIV-infected women with low CD4 cell counts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

12 July 2018

Practical guidelines to interpret plasma concentrations of antiretroviral drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

12 July 2018

Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

12 July 2018

Protein binding in antiretroviral therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

12 July 2018

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

12 July 2018

Human alpha-1-glycoprotein and its interactions with drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

12 July 2018

Plasma protein binding of drugs in pregnancy and in neonates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

12 July 2018

Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

25 September 2018

Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

25 September 2018

Lopinavir/ritonavir in pregnancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

25 September 2018

Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

25 September 2018

The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

25 September 2018

Reduced lopinavir exposure during pregnancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

25 September 2018

Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

25 September 2018

Lopinavir protein binding in vivo through the 12-hour dosing interval

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

25 September 2018

Evaluation of antiretroviral drug measurements by an interlaboratory quality control program

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

25 September 2018

Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3264219

15 November 2018

https://pubmed.ncbi.nlm.nih.gov/22106215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abstracts of the Second Joint Conference of the British HIV Association and the British Association for Sexual Health and HIV. April 20-23, 2010. Manchester, United Kingdom

1 reference

https://pubmed.ncbi.nlm.nih.gov/22106215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection. Glasgow, United Kingdom. November 7-11, 2010

1 reference

https://pubmed.ncbi.nlm.nih.gov/22106215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased rates of preterm delivery are associated with the initiation of highly active antiretrovial therapy during pregnancy: a single-center cohort study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22106215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The AmRo study: pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery

1 reference

https://pubmed.ncbi.nlm.nih.gov/22106215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine

1 reference

https://pubmed.ncbi.nlm.nih.gov/22106215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of lopinavir level between the two formulations (soft-gel capsule and tablet) in HIV-infected pregnant women

1 reference

https://pubmed.ncbi.nlm.nih.gov/22106215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.05186-11

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35689226&oldid=1583696829"